Clinical Trial

A Study to Evaluate Safety and Efficacy of Subcutaneous Administration of Anakinra in Patients With CF

Study acronym: ANAKIN
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
OBJECTIVES Primary: To evaluate efficacy of treatment with anakinra in subjects with CF who are ≥ 12 years of age by means of lung clearance index (LCI). Secondary To evaluate safety and tolerability of treatment with anakinra as well as to investigate further effects of anakinra on lung function and quality of life (QOL) in subjects with CF.
Protocol Amendment History 7 amendments
This ClinicalTrials.gov record has been amended 7 times since 2019-04-19; most recent amendment 2025-03-24.
Status change: Not Yet Recruiting → Recruiting 2022-12-07
Trial Details
NCT Number NCT03925194
Lead Sponsor Heidelberg University
Conditions Cystic Fibrosis, 10011762
Enrollment 52 participants
Start Date 2022-12-01
Primary Completion 2026-12-01 (estimated)
Study Completion 2026-12-01 (estimated)
Updated on ClinicalTrials.gov 2025-03-27